ArticleIJID regions2025
Seroprevalence of SARS-CoV-2 in wet market workers in Dhaka, Bangladesh in 2022.
Article in IJID regions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: We assessed the transmission of SARS-CoV-2 and vaccine receipt in a representative sample of wet market workers in a highly dense, low-income setting. Wet markets are key in many Asian settings, including Dhaka, Bangladesh, for fresh food, including animal protein. Methods: During early 2022, we assessed the prevalence of anti-SARS-CoV-2 antibodies in a random sample of poultry and vegetable workers in 15 wet markets, and investigated associations with socio-demographic characteristics and COVID-19 vaccination. Results: In the 204 poultry workers and 87 vegetable sellers recruited, COVID-19 vaccine uptake was similar (69% vs 67%). The most common vaccines were whole inactivated vaccines (Sinopharm or Sinovac; 44%). Nearly all (99%) participants were positive for anti-SARS-CoV-2 spike antibodies. Anti-SARS-CoV-2 nucleocapsid antibodies, indicative of recent infection, was 59.4% (95% confidence interval 54.7-64.0%). There was no evidence that the latter was associated any characteristics, except vaccination (adjusted odds ratio 0.49; 95% confidence interval 0.23-1.02; Conclusions: The ubiquity of anti-spike and high prevalence of anti-nucleocapsid antibodies were consistent with high transmission after three previous pandemic waves. Wet markets have a potential role amplifying transmission of airborne pathogens, such as SARS-CoV-2 and Avian Influenza Viruses, and an important public-facing hotspot for close monitoring for future emerging infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.